fight-dm1 First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1)
- Coordinator
- Arthex Biotech SL, Spain
- Runs
- 1 January 2023 to 30 June 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €20.1m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190181217
What the project is doing
In the project's own words, from its summary on CORDIS.
Myotonic dystrophy type 1 (DM1) is a clinically and genetically heterogeneous disorder with more than 1 million diagnosed patients worldwide, making it the most common adult muscular dystrophy. Available treatments only relief symptoms. Given this need, we offer ATX-01, a first in class miRNA therapy that inhibits miR-23b without changing the DNA, which rescues DM1 pathogenic mis-splicing. We have demonstrated improved target engagement effects in skeletal and respiratory muscle in in-vitro and in-vivo studies, granting us an FDA pre-IND approval and orphan drug designation.
Our approach, antimiRs conjugated to fatty acids, constitutes the ENTRY platform, which guarantees efficient drug delivery to target muscular and extra-muscular tissue at low doses. This patented technology will be validated through a Phase I/IIa clinical trial and chronic preclinical studies, to then be extended to applications as other myotonic dystrophies, Fuchs dystrophy, cachexia, among other opportunities.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Arthex Biotech SL | Valencia | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI